Key clinical point: Treatment should consider both the risk of bleeding and the likelihood of ischemic and/or limb risk.
Major finding: COMPASS showed that rivaroxaban 2.5 mg twice daily plus daily aspirin decreases major adverse cardiovascular and cerebrovascular events in peripheral arterial disease.
Study details: COMPASS assessed 7,470 patients with peripheral arterial disease or coronary artery disease; this analysis used two case study examples.
Disclosures: Dr. Hussain reported having no conflicts; his coauthors reported receiving funding from various pharmaceutical companies, including Bayer, which was a sponsor of the original COMPASS trial.
Hussain MA et al. Curr Opin Cardiol. 2019;34:178-84.